Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 9/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747563 | 0.86 | ACHE (0.52) | ACHE | |
| SCHEMBL377282 | 0.82 | LIPE (0.51) | SMN1; SMN2ALDH1A1GAAHPGD | |
| SCHEMBL4634509 | 0.81 | SLC7A5 (0.55) | SMN1; SMN2ACHESLC7A5ALDH1A1GAA | |
| SCHEMBL6471295 | 0.81 | HSP90AB1 (0.44) | SMN1; SMN2ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL14051488 | 0.79 | ACHE (0.47) | SMN1; SMN2ACHEALDH1A1 | |
| SCHEMBL31249652 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2SLC7A5ALDH1A1CTBP2POLB | |
| SCHEMBL378705 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2SLC7A5ALDH1A1CTBP2POLB | |
| SCHEMBL12400239 | 0.77 | SLC7A5 (0.68) | SMN1; SMN2SLC7A5ALDH1A1GAAGFER | |
| SCHEMBL3238067 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL2983278 | 0.76 | CYP4F2 (0.46) | ALDH1A1GAAGFERHSP90AB1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090176863-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | MANTLO NATHAN BRYAN | 2009-07-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7504433-B2 | Thiophene derivative PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| EP-1480642-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1583754-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480642-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004063184-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003072102-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176863-A1 | THIOPHENE DERIVATIVE PPAR MODULATORS | PPARA, PPARG, PPARD | SMN1; SMN2 4855/4885ACHE 4487/4885SLC7A5 1455/4885 |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | SMN1; SMN2 4793/4885ACHE 4077/4885SLC7A5 1528/4885 |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | SMN1; SMN2 3427/4885ACHE 4336/4885SLC7A5 1932/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | SMN1; SMN2 4368/4885ACHE 4326/4885SLC7A5 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.